A Phase 2 interventional study of Ceftazidime -avibactam and Meropenem in Complicated Intra-abdominal Infections, sponsored by Pfizer. Completed at 35 sites in 10 countries. Open to participants aged 3 Months to 17 Years. Per ClinicalTrials.gov, last updated 2018-08-09.
Sponsored by Pfizer · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 19 studies in Intraabdominal Infections by Pfizer — none open to participants now, none under way, none of them phase 3. Intraabdominal Infections · Pfizer.
Among the 19 studies in Intraabdominal Infections by Pfizer, this one is the 8th largest by enrollment of the 14 interventional ones that give a count, is one of 2 that started in 2015, is one of 4 in phase 2, and was the 16th registered.
129 studies on the registry are indexed under Intraabdominal Infections; 15 are open to participants now.
Browse Intraabdominal Infections studies →None of the 19 studies in Intraabdominal Infections by Pfizer is open now. The open studies under Intraabdominal Infections, anywhere →
Of the 10 Intraabdominal Infections studies recruiting now, 6 (60%) set no upper age limit and 3 (30%) stop at 75 or younger; 2 take children under 18; 2 take healthy volunteers.
This study: 3 Months to 17 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
19 studies; the count open now beside each. This study's row is marked.
First in 2002; this study’s year is marked. 2 started in 2015.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 83 is below the median of 140 across 77 interventional studies indexed under Intraabdominal Infections.
Median enrollment 144 across the 14 interventional studies, 203 across the 5 observational. Of the 19 that completed or were terminated, 15 (79%) have results posted.
This tab as a report to print or save as PDF → With an account.
Pfizer is the lead sponsor of 3,337 studies on the registry; 150 are open to participants now.
Of its 601 completed or terminated interventional studies of FDA-regulated products, 392 (65%) have results posted.
None of the studies under way reaches primary completion within a year.
Among the 19 studies in Intraabdominal Infections by Pfizer, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
This study will assess the safety , efficacy and pharmacokinetics of ceftazidime avibactam and metronidazole versus meropenem in paediatric population (from 3 months to less than 18 years of age )with complicated intra-abdominal infections (cIAIs)
This is a multicentre, multinational, single blind, randomised and active controlled trial of intravenous ceftazidime avibactam in combination with metronidazole versus meropenem. Patients will receive intravenous (IV) treatment for a minimum of 72 hours (3 full days, ie, 9 doses) before having the option to switch to an oral therapy. The decision to switch to oral therapy is entirely at the Investigator's discretion, if the patient has good or sufficient clinical response, and the patient is tolerating oral fluids or food.Patients will be assessed for safety and efficacy throughout the study, and blood samples will be taken for pharmacokinetic (PK) assessment. The duration of each patient's participation in the study will be a minimum of 27 days to a maximum of 50 days after start of study treatment (defined as the time point at which first dose of study treatment is administered) at which time there will be a late follow up (LFU) assessment visit. The LFU is to be performed 20 to 35 days after the last dose of any treatment.The assessments at the test of cure (TOC) visit should be performed in person 8 to 15 days after last dose of any study drug (IV or oral). The maximum duration of IV study drug or oral switch therapy is up to Day 15.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
At screening:
(i) Patient reports sexual abstinence for the prior 3 months or reports use of at least 1 of the acceptable methods of , including an intrauterine device (with copper banded coil), levonorgestrel intrauterine system (eg, Mirena®), or regular medroxyprogesterone injections (Depo-Provera®); or (b) Patient agrees to initiate sexual abstinence from the time of screening until 7 days after end of treatment with study drug; and (ii) Patient is advised to avoid conception from the time of screening until 7 days after receipt of study drug and agrees not to attempt pregnancy from the time of screening until 7 days after end of treatment with study drug; and (iii) Patient is provided guidelines regarding continuation of abstinence, initiation of abstinence, or about allowed contraception; and (iv) Patient has a negative serum β-human chorionic gonadotropin (β-hCG) test just prior to study entry. Since serum tests may miss an early pregnancy, relevant menstrual history and sexual history, including methods of contraception, should be considered. Note: if the result of the serum β-hCG test cannot be obtained prior to dosing of product, a patient may be enrolled on the basis of a negative urine pregnancy test, though a serum β-hCG test result must still be obtained.
Physical Findings consistent with intra-abdominal infection, such as:
Abdominal pain and/or tenderness Localised or diffuse abdominal wall rigidity Abdominal mass
Visual confirmation of intra-abdominal infection associated with peritonitis at laparotomy, laparoscopy or percutaneous drainage (to be confirmed pending feasibility); must have 1 of these diagnoses:
Exclusion Criteria:
Presence of any of the following laboratory abnormalities:
\<30 mL/min /1.73 m2 calculated using the child's measured height (length) and serum creatinine within the updated "bedside" Schwartz formula (Schwartz et al, 2009):
CrCl (mL/min/1.73m2)=0.413×height (length) (cm)/serum creatinine (mg/dL)
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.
Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.
How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hemoglobin (Hb)
The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ALT and AST (liver enzymes)
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ULN (upper limit of normal)
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Bilirubin
A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.
Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Creatinine clearance (CrCl)
How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
CAZ-AVI to be administered every 8 hours as a 2 hour infusion (CAZ-AVI dose and frequency of IV administration will depend upon body weight and renal function) followed by metronidazole (no later than 30 minutes after CAZ-AVI infusion ) to be administered every 8 hours as 20 to 30 minutes infusion
Drug: Ceftazidime -avibactam · Drug: Metronidazole
administered every 8 hours infused over 15 to 30 minutes or up to 1 hour or infusion duration as per local guidelines.
Drug: Meropenem
Randomisation (3:1) to ceftazidime -avibactam plus metronidazole or meropenem treatment
Randomisation (3:1) to CAZ AVI plus metronidazole or meropenem treatment
Randomisation (3:1) to ceftazidime -avibactam plus metronidazole or meropenem treatment
Percentage of Participants With Treatment-Emergent Adverse Events (AEs) and Serious Adverse Events (SAEs)
An AE was any untoward medical occurrence in a participant who received study drug without regard to possibility of causal relationship. An SAE was an AE resulting in any of the following outcomes or deemed significant for any other reason: death; initial or prolonged in-patient hospitalization; life-threatening experience (immediate risk of dying); persistent or significant disability/incapacity; congenital anomaly. Treatment-emergent AEs were events between first dose of study drug and up to late follow-up (LFU) visit (20 to 35 days after last dose of study treatment \[IV or oral\]) that were absent before treatment or that worsened relative to pretreatment state. AEs included both SAE and non-SAE.
Time frame: Baseline until the LFU visit (up to a maximum study duration of 50 days)
Percentage of Participants With Cephalosporin Class Effects and Additional Adverse Events (AEs)
Percentage of participants with Cephalosporin class effects (defined as adverse event of special interest (AEoSI) within the safety topics (ST) of hypersensitivity/anaphylaxis) and additional AEs (which included AEs of seizures, diarrhea, renal disorder, and liver disorder relevant to the cephalosporin class within the ST and AEs with preferred term in the system organ class of nervous system disorder system organ class based on MedDRA 20.0) were reported in this outcome measure.
Time frame: Baseline until the LFU visit (up to a maximum study duration of 50 days)
Change From Baseline in Pulse Rate at End of Intravenous Therapy (EOIV) Visit
EOIV visit occurred within 24 hours after completion of last infusion of the study drug.
Time frame: Baseline, EOIV visit (anytime from Day 4 up to 16)
Change From Baseline in Systolic Blood Pressure (SBP) and Diastolic Blood Pressure (DBP) at End of Intravenous Therapy (EOIV) Visit
EOIV visit occurred within 24 hours after completion of last infusion of the study drug.
Time frame: Baseline, EOIV visit (anytime from Day 4 up to 16)
Change From Baseline in Respiratory Rate at End of Intravenous Therapy (EOIV) Visit
EOIV visit occurred within 24 hours after completion of last infusion of the study drug.
Time frame: Baseline, EOIV visit (anytime from Day 4 up to 16)
Change From Baseline in Body Weight at End of Intravenous Therapy (EOIV) Visit
EOIV visit occurred within 24 hours after completion of last infusion of the study drug.
Time frame: Baseline, EOIV visit (anytime from Day 4 up to 16)
Change From Baseline in Body Temperature at End of Intravenous Therapy (EOIV) Visit
EOIV visit occurred within 24 hours after completion of last infusion of the study drug.
Time frame: Baseline, EOIV visit (anytime from Day 4 up to 16)
Percentage of Participants With Abnormal Physical Examination Findings at End of Intravenous Therapy (EOIV) Visit
Physical examination included an assessment of the following: general appearance, skin, head and neck (including ears, eyes, nose and throat), lymph nodes, thyroid, respiratory system, cardiovascular system, abdomen, musculoskeletal system (including spine and extremities), and neurological system. Participants with new or aggravated abnormal physical examination findings with regard to baseline findings were reported. Abnormality in physical examinations were based on blinded observer's discretion. EOIV visit occurred within 24 hours after completion of last infusion of the study drug.
Time frame: EOIV visit (anytime from Day 4 up to 16)
Percentage of Participants With Potentially Clinically Significant Abnormalities in Laboratory Parameters
Criteria for potentially clinically significant laboratory abnormalities: Chemistry (calcium: \<0.7\*lower limit of normal range \[LLN\] and \>30 percent decrease from baseline \[DFB\]; alanine aminotransferase \[ALT\]: \>3\*upper limit of normal range \[ULN\] and \>300 percent IFB; alanine aminotransferase \[AST\]: \>3\*ULN and \>300 percent IFB) and hematology (platelets: \>2\*ULN and \>100 percent IFB). LFU visit occurred within 20 to 35 days after last dose of study treatment (IV or oral).
Time frame: Baseline until the LFU visit (up to a maximum study duration of 50 days)
Percentage of Participants With Electrocardiogram (ECG) Parameter QTcF: > 450, >480 and >500 Millisecond (ms)
ECG parameters included maximum QT intervals using Fridericia's correction (QTcF). Maximum QTcF \>450 millisecond (ms); maximum QTcF \>480 ms; and maximum QTcF \>500 ms. EOIV visit occurred within 24 hours after completion of last infusion of the study drug.
Time frame: Baseline until the EOIV visit (anytime from Day 4 to 16)
Percentage of Participants With Creatinine Clearance (CrCl) at Day 7
CrCl is a measure of glomerular filtration rate (GMFR), an index of kidney function. It is the volume of blood plasma that is cleared of creatinine by the kidneys per unit time. Percentage of participants with CrCl in the following categories were reported: \<30 mL/min/1.73 m\^2, \>=30 to \<50 mL/min/1.73 m\^2, \>=50 mL/min/1.73 m\^2 to \<80 mL/min/1.73 m\^2, and \>=80 mL/min/1.73 m\^2.
Time frame: Day 7
Percentage of Participants With Creatinine Clearance (CrCl) at End of Intravenous Therapy (EOIV) Visit
CrCl is a measure of GMFR, an index of kidney function. It is the volume of blood plasma that is cleared of creatinine by the kidneys per unit time. Percentage of participants with CrCl in the following categories were reported: \<30 mL/min/1.73 m\^2, \>=30 to \<50 mL/min/1.73 m\^2, \>=50 mL/min/1.73 m\^2 to \<80 mL/min/1.73 m\^2, and \>=80 mL/min/1.73 m\^2. EOIV visit occurred within 24 hours after completion of last infusion of the study drug.
Time frame: EOIV visit (anytime from Day 4 up to 16)
Percentage of Participants With Creatinine Clearance (CrCl) at Test of Cure (TOC) Visit
CrCl is a measure of GMFR, an index of kidney function. It is the volume of blood plasma that is cleared of creatinine by the kidneys per unit time. Percentage of participants with CrCl in the following categories were reported: \<30 mL/min/1.73 m\^2, \>=30 to \<50 mL/min/1.73 m\^2, \>=50 mL/min/1.73 m\^2 to \<80 mL/min/1.73 m\^2, and \>=80 mL/min/1.73 m\^2. TOC visit occurred within 8 to 15 days after last dose of any study drug (IV or oral).
Time frame: TOC visit (up to a maximum study duration of 50 days)
Percentage of Participants With Creatinine Clearance (CrCl) at Late Follow-up (LFU) Visit
CrCl is a measure of GMFR, an index of kidney function. It is the volume of blood plasma that is cleared of creatinine by the kidneys per unit time. Percentage of participants with CrCl in the following categories were reported: \<30 mL/min/1.73 m\^2, \>=30 to \<50 mL/min/1.73 m\^2, \>=50 mL/min/1.73 m\^2 to \<80 mL/min/1.73 m\^2, and \>=80 mL/min/1.73 m\^2. LFU visit occurred within 20 to 35 days after last dose of study treatment (IV or oral).
Time frame: LFU visit (up to a maximum study duration of 50 days)
Plasma Concentrations of Ceftazidime and Avibactam
Time frame: 15, 30-90, 300-360 minutes post-dose on Day 3
Percentage of Participants With Favorable Clinical Response (CR) at End of 72 Hours Treatment: Intent-to-treat (ITT) Analysis Population
Favorable CR was defined as resolution of all acute signs and symptoms of complicated intra- abdominal infection (cIAIs), or improvement to such an extent that no further antimicrobial therapy was required, or improvement but not enough to switch to oral therapy and still on IV study drug at end of 72 hours and had met following criterion: absence of new signs and symptoms, improvement in at least 1 symptom/sign (fever, pain, tenderness, elevated White Blood Cells \[WBCs\], elevated c-reactive protein) from baseline and no worsening symptom/sign.
Time frame: End of 72 hours study drug treatment on Day 1
Percentage of Participants With Favorable Clinical Response (CR) at End of Intravenous Therapy (EOIV) Visit: Intent-to-treat (ITT) Analysis Population
Favorable CR was resolution of all acute signs and symptoms of cIAI or improvement to such an extent that no further antimicrobial therapy was required, or improvement in participants who had switch to oral therapy and met the following criterion: afebrile (temperature \<=38.0°C) for at least 24 hours, absence of new and improvement in at least 1 symptom or sign (fever, pain, tenderness, elevated WBCs, elevated c-reative-protein) from baseline and worsening of none. EOIV visit occurred within 24 hours after completion of last infusion of the study drug.
Time frame: EOIV visit (anytime from Day 4 up to 16)
Percentage of Participants With Favorable Clinical Response (CR) at End of Treatment (EOT) Visit: Intent-to-treat (ITT) Analysis Population
Favorable CR was resolution of all acute signs and symptoms of cIAI, or improvement to such an extent that no further antimicrobial therapy was required. EOT visit occurred within 48 hours after completion of the last dose of oral switch therapy or at time of premature discontinuation/early withdrawal from study (if on oral switch therapy).
Time frame: EOT visit (up to Day 17)
Percentage of Participants With Favorable Clinical Response (CR) at Test of Cure (TOC) Visit: Intent-to-treat (ITT) Analysis Population
Favorable CR was resolution of all acute signs and symptoms of cIAI, or improvement to such an extent that no further antimicrobial therapy was required. TOC visit occurred within 8 to 15 days after last dose of any study drug (IV or oral).
Time frame: TOC visit (up to a maximum study duration of 50 days)
Percentage of Participants With Favorable Clinical Response (CR): Clinically Evaluable (CE) Analysis Population
Favorable CR was resolution of all acute signs and symptoms of cIAI, or improvement to such an extent that no further antimicrobial therapy was required, or improvement in participants who had switch to oral therapy and met the following criterion: afebrile (temperature \<=38.0°C) for at least 24 hours, absence of new and improvement in at least 1 symptom or sign (fever, pain, tenderness, elevated WBCs, elevated c-reative-protein) from baseline and worsening of none. EOIV visit occurred within 24 hours after completion of last infusion of the study drug. EOT visit occurred within 48 hours after completion of last dose of oral switch therapy or at time of premature discontinuation/early withdrawal from study (if on oral switch therapy). TOC visit occurred within 8 to 15 days after last dose of any study drug (IV or oral).
Time frame: End of 72 hours study drug treatment on Day 1, EOIV (anytime from Day 4 up to 16), EOT visit (up to Day 17) and TOC visit (up to a maximum study duration of 50 days)
Percentage of Participants With Favorable Microbiological Response: Microbiological Intent-to-treat (Micro-ITT) Population
Favorable microbiological response was achieved when all baseline pathogens were eradicated or presumed eradicated based on investigator's discretion. EOIV visit occurred within 24 hours after completion of last infusion of the study drug. EOT visit occurred within 48 hours after completion of last dose of oral switch therapy or at time of premature discontinuation/early withdrawal from study if on oral switch therapy (which occurred within the maximum study treatment duration of 15 days). EOIV visit occurred within 24 hours after completion of last infusion of the study drug. TOC visit occurred within 8 to 15 days after last dose of any study drug (IV or oral). LFU visit occurred within 20 to 35 days after last dose of study treatment (IV or oral).
Time frame: EOIV visit (Day 4 up to 16), EOT visit (up to Day 17), TOC visit (up to a maximum study duration of 50 days) and LFU visit (up to a maximum study duration of 50 days)
Percentage of Participants With Favorable Microbiological Response: Microbiologically Evaluable (ME) Population
Favorable microbiological response was achieved when all baseline pathogens were eradicated or presumed eradicated based on investigator's discretion. EOIV visit occurred within 24 hours after completion of last infusion of the study drug. EOT visit occurred within 48 hours after completion of last dose of oral switch therapy or at time of premature discontinuation/early withdrawal from study if on oral switch therapy (which occurred within the maximum study treatment duration of 15 days). TOC visit occurred within 8 to 15 days after last dose of any study drug (IV or oral). LFU visit occurred within 20 to 35 days after last dose of study treatment (IV or oral).
Time frame: EOIV visit (Day 4 up to 16), EOT visit (up to Day 17), TOC visit (up to a maximum study duration of 50 days) and LFU visit (up to a maximum study duration of 50 days)
Percentage of Participants With Clinical Relapse at Late Follow-up (LFU) Visit: Clinically Evaluable (CE) Population
A participant was said to have clinical relapse if met either 1 of the following criteria: reappearance or worsening of signs and symptoms of cIAI that required further antimicrobial therapy and/or surgery, or death after TOC in which cIAI was contributory. LFU visit occurred within 20 to 35 days after last dose of study treatment (IV or oral).
Time frame: LFU visit (up to a maximum study duration of 50 days)
Percentage of Participants With Clinical Relapse at Late Follow-up (LFU) Visit: Microbiologically Evaluable (ME) Population
A participant was said to have clinical relapse if me either 1 of the following criteria: reappearance or worsening of signs and symptoms of cIAI that required further antimicrobial therapy and/or surgery, or death after TOC in which cIAI was contributory. LFU visit occurred within 20 to 35 days after last dose of study treatment (IV or oral).
Time frame: LFU visit (up to a maximum study duration of 50 days)
Percentage of Participants With Emergent Infections: Microbiological Intent-to-treat (Micro-ITT) Population
Emergent infections were categorized as super infections and new infections. Superinfection: An intra-abdominal culture identified pathogen other than a baseline pathogen during the course of active treatment with study therapy along with worsening signs and symptoms of infection requiring alternative antimicrobial therapy. New infection: An intra-abdominal culture identified pathogen other than a baseline pathogen at any time after study treatment had finished along with worsening signs and symptoms of infection requiring alternative antimicrobial therapy. Participants with any (super infections or new infections) of the infections were reported.
Time frame: Baseline up to 50 days
Percentage of Participants With Emergent Infections at Test of Cure (TOC) Visit: Microbiologically Evaluable Population
Emergent Infections was an intra-abdominal culture identified pathogen other than a baseline pathogen during the course of active treatment with study therapy along with worsening signs and symptoms of infection requiring alternative antimicrobial therapy, new infection was an intra-abdominal culture identified pathogen other than a baseline pathogen at any time after study treatment has finished along with worsening signs and symptoms of infection requiring alternative antimicrobial therapy. TOC visit occurred within 8 to 15 days after last dose of any study drug (IV or oral). Participants with any (super infections or new infections) of the infections were reported.
Time frame: TOC visit (up to a maximum study duration of 50 days)
| Milestone | Ceftazidime- Avibactam (CAZ-AVI) Plus Metronidazole | Meropenem |
|---|---|---|
| Started | 61 | 22 |
| Completed | 59 | 22 |
| Not completed | 2 | 0 |
| Withdrew: Withdrawal by subject | 1 | 0 |
| Withdrew: Physician decision | 1 | 0 |
An AE was any untoward medical occurrence in a participant who received study drug without regard to possibility of causal relationship. An SAE was an AE resulting in any of the following outcomes or deemed significant for any other reason: death; initial or prolonged in-patient hospitalization; life-threatening experience (immediate risk of dying); persistent or significant disability/incapacity; congenital anomaly. Treatment-emergent AEs were events between first dose of study drug and up to late follow-up (LFU) visit (20 to 35 days after last dose of study treatment \[IV or oral\]) that were absent before treatment or that worsened relative to pretreatment state. AEs included both SAE and non-SAE.
| percentage of participants | Ceftazidime- Avibactam (CAZ-AVI) Plus Metronidazole | Meropenem |
|---|---|---|
| AEs | 52.5 | 59.1 |
| SAEs | 8.2 | 4.5 |
Percentage of participants with Cephalosporin class effects (defined as adverse event of special interest (AEoSI) within the safety topics (ST) of hypersensitivity/anaphylaxis) and additional AEs (which included AEs of seizures, diarrhea, renal disorder, and liver disorder relevant to the cephalosporin class within the ST and AEs with preferred term in the system organ class of nervous system disorder system organ class based on MedDRA 20.0) were reported in this outcome measure.
| percentage of participants | Ceftazidime- Avibactam (CAZ-AVI) Plus Metronidazole | Meropenem |
|---|---|---|
| AE in the ST of Diarrhea | 1.6 | 0 |
| AEoSI in the ST of Hypersensitivity/Anaphylaxis | 4.9 | 13.6 |
| AE in the ST of Liver Disorder | 0 | 0 |
| AE in the ST of Renal Disorder | 0 | 0 |
| AEs with PTs in the Nervous System Disorder SOC | 1.6 | 4.5 |
| AE of seizure | 0 | 0 |
EOIV visit occurred within 24 hours after completion of last infusion of the study drug.
| beats per minute | Ceftazidime- Avibactam (CAZ-AVI) Plus Metronidazole | Meropenem |
|---|---|---|
| Baseline | 102.1 ± 17.07 | 103.0 ± 23.31 |
| Change at EOIV | -15.2 ± 20.45 | -15.4 ± 21.74 |
EOIV visit occurred within 24 hours after completion of last infusion of the study drug.
| millimeter of mercury (mmHg) | Ceftazidime- Avibactam (CAZ-AVI) Plus Metronidazole | Meropenem |
|---|---|---|
| SBP: Baseline | 109.7 ± 13.90 | 111.6 ± 13.06 |
| SBP: Change at EOIV | -4.0 ± 12.32 | -6.0 ± 13.66 |
| DBP: Baseline | 63.5 ± 10.36 | 63.1 ± 13.51 |
| DBP: Change at EOIV | 1.3 ± 11.99 | -2.8 ± 14.14 |
EOIV visit occurred within 24 hours after completion of last infusion of the study drug.
| breaths per minute | Ceftazidime- Avibactam (CAZ-AVI) Plus Metronidazole | Meropenem |
|---|---|---|
| Baseline | 22.4 ± 5.02 | 22.9 ± 5.79 |
| Change at EOIV | -1.3 ± 4.57 | -1.3 ± 4.44 |
EOIV visit occurred within 24 hours after completion of last infusion of the study drug.
| kilograms | Ceftazidime- Avibactam (CAZ-AVI) Plus Metronidazole | Meropenem |
|---|---|---|
| Baseline | 40.58 ± 16.286 | 38.35 ± 16.685 |
| Change at EOIV | -0.38 ± 1.442 | -1.06 ± 1.490 |
EOIV visit occurred within 24 hours after completion of last infusion of the study drug.
| degree Celsius | Ceftazidime- Avibactam (CAZ-AVI) Plus Metronidazole | Meropenem |
|---|---|---|
| Baseline | 37.35 ± 1.035 | 37.16 ± 0.914 |
| Change at EOIV | -0.78 ± 0.987 | -0.60 ± 0.780 |
Physical examination included an assessment of the following: general appearance, skin, head and neck (including ears, eyes, nose and throat), lymph nodes, thyroid, respiratory system, cardiovascular system, abdomen, musculoskeletal system (including spine and extremities), and neurological system. Participants with new or aggravated abnormal physical examination findings with regard to baseline findings were reported. Abnormality in physical examinations were based on blinded observer's discretion. EOIV visit occurred within 24 hours after completion of last infusion of the study drug.
| percentage of participants | Ceftazidime- Avibactam (CAZ-AVI) Plus Metronidazole | Meropenem |
|---|---|---|
| Abdomen | 6.6 | 18.2 |
| Cardiovascular System | 0 | 0 |
| General Appearance | 1.6 | 0 |
| Head and Neck | 0 | 0 |
| Lymph Nodes | 0 | 0 |
| Musculoskeletal System | 0 | 0 |
| Neurological System | 0 | 0 |
| Respiratory System | 3.3 | 0 |
| Skin | 1.6 | 0 |
| Thyroid | 0 | 0 |
Criteria for potentially clinically significant laboratory abnormalities: Chemistry (calcium: \<0.7\*lower limit of normal range \[LLN\] and \>30 percent decrease from baseline \[DFB\]; alanine aminotransferase \[ALT\]: \>3\*upper limit of normal range \[ULN\] and \>300 percent IFB; alanine aminotransferase \[AST\]: \>3\*ULN and \>300 percent IFB) and hematology (platelets: \>2\*ULN and \>100 percent IFB). LFU visit occurred within 20 to 35 days after last dose of study treatment (IV or oral).
| percentage of participants | Ceftazidime- Avibactam (CAZ-AVI) Plus Metronidazole | Meropenem |
|---|---|---|
| Chemistry: Calcium | 1.9 | 0 |
| Chemistry: ALT | 1.7 | 0 |
| Chemistry: AST | 1.8 | 0 |
| Hematology: Platelets | 3.3 | 0 |
ECG parameters included maximum QT intervals using Fridericia's correction (QTcF). Maximum QTcF \>450 millisecond (ms); maximum QTcF \>480 ms; and maximum QTcF \>500 ms. EOIV visit occurred within 24 hours after completion of last infusion of the study drug.
| percentage of participants | Ceftazidime- Avibactam (CAZ-AVI) Plus Metronidazole | Meropenem |
|---|---|---|
| Maximum QTcF Interval : >450 ms | 1.6 | 4.5 |
| Maximum QTcF Interval : >480 ms | 1.6 | 4.5 |
| Maximum QTcF Interval : >500 ms | 0 | 4.5 |
CrCl is a measure of glomerular filtration rate (GMFR), an index of kidney function. It is the volume of blood plasma that is cleared of creatinine by the kidneys per unit time. Percentage of participants with CrCl in the following categories were reported: \<30 mL/min/1.73 m\^2, \>=30 to \<50 mL/min/1.73 m\^2, \>=50 mL/min/1.73 m\^2 to \<80 mL/min/1.73 m\^2, and \>=80 mL/min/1.73 m\^2.
| percentage of participants | Ceftazidime- Avibactam (CAZ-AVI) Plus Metronidazole | Meropenem |
|---|---|---|
| CrCl: <30mL/min/1.73 m^2 | 0 | 0 |
| CrCl: >=30 to <50mL/min/1.73 m^2 | 0 | 0 |
| CrCl: >=50 to <80mL/min/1.73 m^2 | 0 | 0 |
| CrCl: >=80mL/min/1.73 m^2 | 50.8 | 59.1 |
CrCl is a measure of GMFR, an index of kidney function. It is the volume of blood plasma that is cleared of creatinine by the kidneys per unit time. Percentage of participants with CrCl in the following categories were reported: \<30 mL/min/1.73 m\^2, \>=30 to \<50 mL/min/1.73 m\^2, \>=50 mL/min/1.73 m\^2 to \<80 mL/min/1.73 m\^2, and \>=80 mL/min/1.73 m\^2. EOIV visit occurred within 24 hours after completion of last infusion of the study drug.
| percentage of participants | Ceftazidime- Avibactam (CAZ-AVI) Plus Metronidazole | Meropenem |
|---|---|---|
| CrCl: <30mL/min/1.73 m^2 | 0 | 0 |
| CrCl: >=30 to <50mL/min/1.73 m^2 | 0 | 0 |
| CrCl: >=50 to <80mL/min/1.73 m^2 | 0 | 0 |
| CrCl: >=80mL/min/1.73 m^2 | 82.0 | 81.8 |
CrCl is a measure of GMFR, an index of kidney function. It is the volume of blood plasma that is cleared of creatinine by the kidneys per unit time. Percentage of participants with CrCl in the following categories were reported: \<30 mL/min/1.73 m\^2, \>=30 to \<50 mL/min/1.73 m\^2, \>=50 mL/min/1.73 m\^2 to \<80 mL/min/1.73 m\^2, and \>=80 mL/min/1.73 m\^2. TOC visit occurred within 8 to 15 days after last dose of any study drug (IV or oral).
| percentage of participants | Ceftazidime- Avibactam (CAZ-AVI) Plus Metronidazole | Meropenem |
|---|---|---|
| CrCl: <30mL/min/1.73 m^2 | 0 | 0 |
| CrCl: >=30 to <50mL/min/1.73 m^2 | 0 | 0 |
| CrCl: >=50 to <80mL/min/1.73 m^2 | 3.3 | 0 |
| CrCl: >=80mL/min/1.73 m^2 | 42.6 | 59.1 |
CrCl is a measure of GMFR, an index of kidney function. It is the volume of blood plasma that is cleared of creatinine by the kidneys per unit time. Percentage of participants with CrCl in the following categories were reported: \<30 mL/min/1.73 m\^2, \>=30 to \<50 mL/min/1.73 m\^2, \>=50 mL/min/1.73 m\^2 to \<80 mL/min/1.73 m\^2, and \>=80 mL/min/1.73 m\^2. LFU visit occurred within 20 to 35 days after last dose of study treatment (IV or oral).
| percentage of participants | Ceftazidime- Avibactam (CAZ-AVI) Plus Metronidazole | Meropenem |
|---|---|---|
| CrCl: <30mL/min/1.73 m^2 | 0 | 0 |
| CrCl: >=30 to <50mL/min/1.73 m^2 | 0 | 0 |
| CrCl: >=50 to <80mL/min/1.73 m^2 | 1.6 | 0 |
| CrCl: >=80mL/min/1.73 m^2 | 6.6 | 9.1 |
| nanogram per milliliter | Ceftazidime- Avibactam (CAZ-AVI) Plus Metronidazole |
|---|---|
| Ceftazidime: 15 minute post-dose on Day 3 | 63565.5 ± 236761.80 |
| Ceftazidime: 30-90 minute post-dose on Day 3 | 38048.0 ± 19810.95 |
| Ceftazidime:300-360minute post-dose on Day 3 | 4603.0 ± 10308.96 |
| Avibactam: 15 minute post-dose on Day 3 | 12186.2 ± 55720.44 |
| Avibactam: 30-90 minute post-dose on Day 3 | 6548.6 ± 4437.55 |
| Avibactam: 300-360 minute post-dose on Day 3 | 821.5 ± 1968.21 |
Favorable CR was defined as resolution of all acute signs and symptoms of complicated intra- abdominal infection (cIAIs), or improvement to such an extent that no further antimicrobial therapy was required, or improvement but not enough to switch to oral therapy and still on IV study drug at end of 72 hours and had met following criterion: absence of new signs and symptoms, improvement in at least 1 symptom/sign (fever, pain, tenderness, elevated White Blood Cells \[WBCs\], elevated c-reactive protein) from baseline and no worsening symptom/sign.
| percentage of participants | Ceftazidime- Avibactam (CAZ-AVI) Plus Metronidazole | Meropenem |
|---|---|---|
| Percentage of Participants With Favorable Clinical Response (CR) at End of 72 Hours Treatment: Intent-to-treat (ITT) Analysis Population | 93.4 (85.2 to 97.7) | 90.9 (73.9 to 98.1) |
Favorable CR was resolution of all acute signs and symptoms of cIAI or improvement to such an extent that no further antimicrobial therapy was required, or improvement in participants who had switch to oral therapy and met the following criterion: afebrile (temperature \<=38.0°C) for at least 24 hours, absence of new and improvement in at least 1 symptom or sign (fever, pain, tenderness, elevated WBCs, elevated c-reative-protein) from baseline and worsening of none. EOIV visit occurred within 24 hours after completion of last infusion of the study drug.
| percentage of participants | Ceftazidime- Avibactam (CAZ-AVI) Plus Metronidazole | Meropenem |
|---|---|---|
| Percentage of Participants With Favorable Clinical Response (CR) at End of Intravenous Therapy (EOIV) Visit: Intent-to-treat (ITT) Analysis Population | 96.7 (89.9 to 99.3) | 100 (89.3 to 100) |
Favorable CR was resolution of all acute signs and symptoms of cIAI, or improvement to such an extent that no further antimicrobial therapy was required. EOT visit occurred within 48 hours after completion of the last dose of oral switch therapy or at time of premature discontinuation/early withdrawal from study (if on oral switch therapy).
| percentage of participants | Ceftazidime- Avibactam (CAZ-AVI) Plus Metronidazole | Meropenem |
|---|---|---|
| Percentage of Participants With Favorable Clinical Response (CR) at End of Treatment (EOT) Visit: Intent-to-treat (ITT) Analysis Population | 91.8 (83.0 to 96.8) | 100 (89.3 to 100) |
Favorable CR was resolution of all acute signs and symptoms of cIAI, or improvement to such an extent that no further antimicrobial therapy was required. TOC visit occurred within 8 to 15 days after last dose of any study drug (IV or oral).
| percentage of participants | Ceftazidime- Avibactam (CAZ-AVI) Plus Metronidazole | Meropenem |
|---|---|---|
| Percentage of Participants With Favorable Clinical Response (CR) at Test of Cure (TOC) Visit: Intent-to-treat (ITT) Analysis Population | 91.8 (83.0 to 96.8) | 95.5 (80.7 to 99.5) |
Favorable CR was resolution of all acute signs and symptoms of cIAI, or improvement to such an extent that no further antimicrobial therapy was required, or improvement in participants who had switch to oral therapy and met the following criterion: afebrile (temperature \<=38.0°C) for at least 24 hours, absence of new and improvement in at least 1 symptom or sign (fever, pain, tenderness, elevated WBCs, elevated c-reative-protein) from baseline and worsening of none. EOIV visit occurred within 24 hours after completion of last infusion of the study drug. EOT visit occurred within 48 hours after completion of last dose of oral switch therapy or at time of premature discontinuation/early withdrawal from study (if on oral switch therapy). TOC visit occurred within 8 to 15 days after last dose of any study drug (IV or oral).
| percentage of participants | Ceftazidime- Avibactam (CAZ-AVI) Plus Metronidazole | Meropenem |
|---|---|---|
| End 72 hours study medication | 98.0 (90.9 to 99.8) | 95.0 (78.9 to 99.5) |
| EOIV | 98.1 (91.7 to 99.8) | 100 (88.3 to 100) |
| EOT | 94.2 (85.4 to 98.3) | 100 (88.3 to 100) |
| TOC | 92.9 (83.9 to 97.5) | 95.0 (78.9 to 99.5) |
Favorable microbiological response was achieved when all baseline pathogens were eradicated or presumed eradicated based on investigator's discretion. EOIV visit occurred within 24 hours after completion of last infusion of the study drug. EOT visit occurred within 48 hours after completion of last dose of oral switch therapy or at time of premature discontinuation/early withdrawal from study if on oral switch therapy (which occurred within the maximum study treatment duration of 15 days). EOIV visit occurred within 24 hours after completion of last infusion of the study drug. TOC visit occurred within 8 to 15 days after last dose of any study drug (IV or oral). LFU visit occurred within 20 to 35 days after last dose of study treatment (IV or oral).
| percentage of participants | Ceftazidime- Avibactam (CAZ-AVI) Plus Metronidazole | Meropenem |
|---|---|---|
| EOIV | 96.0 | 100 |
| EOT | 90.0 | 100 |
| TOC | 90.0 | 94.7 |
| LFU | 90.0 | 94.7 |
Favorable microbiological response was achieved when all baseline pathogens were eradicated or presumed eradicated based on investigator's discretion. EOIV visit occurred within 24 hours after completion of last infusion of the study drug. EOT visit occurred within 48 hours after completion of last dose of oral switch therapy or at time of premature discontinuation/early withdrawal from study if on oral switch therapy (which occurred within the maximum study treatment duration of 15 days). TOC visit occurred within 8 to 15 days after last dose of any study drug (IV or oral). LFU visit occurred within 20 to 35 days after last dose of study treatment (IV or oral).
| percentage of participants | Ceftazidime- Avibactam (CAZ-AVI) Plus Metronidazole | Meropenem |
|---|---|---|
| EOIV | 97.5 | 100 |
| EOT | 91.7 | 100 |
| TOC | 90.0 | 93.3 |
| LFU | 89.2 | 92.9 |
A participant was said to have clinical relapse if met either 1 of the following criteria: reappearance or worsening of signs and symptoms of cIAI that required further antimicrobial therapy and/or surgery, or death after TOC in which cIAI was contributory. LFU visit occurred within 20 to 35 days after last dose of study treatment (IV or oral).
| percentage of participants | Ceftazidime- Avibactam (CAZ-AVI) Plus Metronidazole | Meropenem |
|---|---|---|
| Percentage of Participants With Clinical Relapse at Late Follow-up (LFU) Visit: Clinically Evaluable (CE) Population | 0 | 0 |
A participant was said to have clinical relapse if me either 1 of the following criteria: reappearance or worsening of signs and symptoms of cIAI that required further antimicrobial therapy and/or surgery, or death after TOC in which cIAI was contributory. LFU visit occurred within 20 to 35 days after last dose of study treatment (IV or oral).
| percentage of participants | Ceftazidime- Avibactam (CAZ-AVI) Plus Metronidazole | Meropenem |
|---|---|---|
| Percentage of Participants With Clinical Relapse at Late Follow-up (LFU) Visit: Microbiologically Evaluable (ME) Population | 0 | 0 |
Emergent infections were categorized as super infections and new infections. Superinfection: An intra-abdominal culture identified pathogen other than a baseline pathogen during the course of active treatment with study therapy along with worsening signs and symptoms of infection requiring alternative antimicrobial therapy. New infection: An intra-abdominal culture identified pathogen other than a baseline pathogen at any time after study treatment had finished along with worsening signs and symptoms of infection requiring alternative antimicrobial therapy. Participants with any (super infections or new infections) of the infections were reported.
| percentage of participants | Ceftazidime- Avibactam (CAZ-AVI) Plus Metronidazole | Meropenem |
|---|---|---|
| Percentage of Participants With Emergent Infections: Microbiological Intent-to-treat (Micro-ITT) Population | 0 | 0 |
Emergent Infections was an intra-abdominal culture identified pathogen other than a baseline pathogen during the course of active treatment with study therapy along with worsening signs and symptoms of infection requiring alternative antimicrobial therapy, new infection was an intra-abdominal culture identified pathogen other than a baseline pathogen at any time after study treatment has finished along with worsening signs and symptoms of infection requiring alternative antimicrobial therapy. TOC visit occurred within 8 to 15 days after last dose of any study drug (IV or oral). Participants with any (super infections or new infections) of the infections were reported.
| percentage of participants | Ceftazidime- Avibactam (CAZ-AVI) Plus Metronidazole | Meropenem |
|---|---|---|
| Percentage of Participants With Emergent Infections at Test of Cure (TOC) Visit: Microbiologically Evaluable Population | 0 | 0 |
Collected over Baseline until the LFU visit (up to a maximum study duration of 50 days). Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Ceftazidime- Avibactam (CAZ-AVI) Plus Metronidazole | 0/61 (0%) | 5/61 (8.2%) | 14/61 (23%) |
| Meropenem | 0/22 (0%) | 1/22 (4.5%) | 6/22 (27.3%) |
| Event | Ceftazidime- Avibactam (CAZ-AVI) Plus Metronidazole | Meropenem |
|---|---|---|
| IleusGastrointestinal disorders | 1/61 | 1/22 |
| Intestinal obstructionGastrointestinal disorders | 1/61 | 0/22 |
| Large intestine perforationGastrointestinal disorders | 1/61 | 0/22 |
| Postoperative ileusInjury, poisoning and procedural complications | 1/61 | 0/22 |
| Renal colicRenal and urinary disorders | 1/61 | 0/22 |
| Urethral meatus stenosisRenal and urinary disorders | 1/61 | 0/22 |
| Event | Ceftazidime- Avibactam (CAZ-AVI) Plus Metronidazole | Meropenem |
|---|---|---|
| VomitingGastrointestinal disorders | 9/61 | 2/22 |
| Abdominal painGastrointestinal disorders | 0/61 | 2/22 |
| CoughRespiratory, thoracic and mediastinal disorders | 1/61 | 2/22 |
| Infusion site phlebitisGeneral disorders | 4/61 | 0/22 |
Intent-to-treat (ITT) analysis set included all participants who had been assigned a randomized treatment.
| Age, Continuous(years) | Ceftazidime- Avibactam (CAZ-AVI) Plus Metronidazole | Meropenem | Total |
|---|---|---|---|
| Mean | 10.4 ± 3.64 | 9.7 ± 3.97 | 10.2 ± 3.71 |
| Sex: Female, Male(Participants) | Ceftazidime- Avibactam (CAZ-AVI) Plus Metronidazole | Meropenem | Total |
|---|---|---|---|
| Female | 17 | 13 | 30 |
| Male | 44 | 9 | 53 |
| Ethnicity (NIH/OMB)(Participants) | Ceftazidime- Avibactam (CAZ-AVI) Plus Metronidazole | Meropenem | Total |
|---|---|---|---|
| Hispanic or Latino | 12 | 1 | 13 |
| Not Hispanic or Latino | 49 | 21 | 70 |
| Unknown or Not Reported | 0 | 0 | 0 |
| Race (NIH/OMB)(Participants) | Ceftazidime- Avibactam (CAZ-AVI) Plus Metronidazole | Meropenem | Total |
|---|---|---|---|
| American Indian or Alaska Native | 1 | 0 | 1 |
| Asian | 7 | 4 | 11 |
| Native Hawaiian or Other Pacific Islander | 0 | 0 | 0 |
| Black or African American | 0 | 0 | 0 |
| White | 53 | 16 | 69 |
| More than one race | 0 | 0 | 0 |
| Unknown or Not Reported | 0 | 2 | 2 |
PDFs hosted by the registry, ClinicalTrials.gov.
Ran from Aug 2015 to primary completion in Jun 2017, 22 months.
Results were first posted in Aug 2018, 1 year 2 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Jul 2018. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Metronidazole